According to researchers, their findings warrant close surveillance of weight and BMI/age z-scores for patients with type 2 spinal muscular atrophy (SMA).
New study findings are highlighting a common feature of type 2 spinal muscular atrophy (SMA), revealing that low body mass index (BMI)/age z-score is often seen in patients with the SMA subtype. They also show that baseline scores and gender play a role in further reductions as patients age.
Findings were published in European Journal of Pediatrics.
According to the researchers, their findings warrant close surveillance of weight and BMI/age z-scores for patients with type 2 SMA and that more studies will be helpful in better understanding the possible mechanisms underlying weight issues.
The group used data from nearly 350 visits from 100 patients in Italy, finding that 28% of the measurements showed a BMI/age z-score 2 standard deviations (SDs) below. According to the researchers, there was a relatively small number of patients who had an assessment with a BMI/age z-score above 2 SDs; this was primarily observed in male patients younger than 13 years.
Across age groups, results were relatively stable for patients under the age of 5 years, after which the number of patients with BMI/age z-score 2 SDs below increased.
“The lowest BMI/age z-scores were mainly observed in patients older than 12 years in whom the BMI/age z-score values were often already [2 SDs below] at first assessment, irrespective of the age when the first assessment was performed,” wrote the researchers. “This occurred more frequently in male patients. At the other end of the spectrum, a number of boys who were [2 SDs above] between the ages of 5 and 12 shifted to ± 2SD when approaching puberty.”
Longer-term follow-up was available for 58 of the patients included in the study, offering further insights. These patients had more than 1 follow-up visited documented in the data, with a median follow-up of nearly 4 years.
These additional results revealed that baseline BMI/age z-scores and gender had significant associations with changes in scores. Among the patients included in the longer-term follow-up who after the age of 13 years had BMI/age z-score 5 SDs below, all but 1 already had baseline BMI/age z-score 2 SDs below, regardless of their age at baseline. Between genders, male patients exhibited more obvious weight changes at both extremes of the range.
SMN2 copy number, SMA function, noninvasive ventilation, nutritional status, and scoliosis surgery were not found to have a significant impact on the rate of progression.
“At variance with other studies, we had a low number of patients who underwent gastrostomy, despite the low BMI. Only 2 of the patients had a history of swallowing problems, and/or aspiration pneumonia, and they both underwent gastrostomy,” wrote the researchers. “In all the others, after introduction of supplements and dietary recommendations, the possibility of a percutaneous endoscopic gastrostomy was discussed, but as the majority of the cases with very low BMI were in their teens, they would not accept this option for a variety of reasons, including issues related to body image.”
Reference
Ferrantini G, Coratti G, Onesimo R, et al. Body mass index in type 2 spinal muscular atrophy: a longitudinal study. Eur J Pediatr. Published online January 19, 2022. doi:10.1007/s00431-021-04325-3
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More